Selective loss of δ opioid analgesia and binding by antisense oligodeoxynucleotides to a δ opioid receptor

Kelly M. Standifer, Chih Cheng Chien, Claes R Wahlestedt, George P. Brown, Gavril W. Pasternak

Research output: Contribution to journalArticle

183 Citations (Scopus)

Abstract

Antisense oligodeoxynucleotides (18-20 bases) to a cloned δ opioid receptor (DOR-1) lower δ binding in NG108-15 cells by 40%-50%. Changing 4 bases to generate a mismatch antisense oligodeoxynucleotide or mixing the corresponding sense and antisense oligodeoxynucleotides prior to treatment of the cells eliminates the inhibition of binding, confirming the specificity of the response. In vivo, an antisense oligodeoxynucleotide to DOR-1 given intrathecally lowers δ, but not μ or κ1 spinal analgesia. The mismatch antisense oligodeoxynucleotide is inactive. δ analgesic sensitivity gradually returns by 5 days after the last antisense treatment, indicating the lack of irreversible damage or toxicity. These studies demonstrate that DOR-1 mediates δ analgesia at the level of the spinal cord and confirm at the molecular level traditional pharmacological studies implying distinct receptor mechanisms for δ, μ, and κ1 analgesia. The use of antisense approaches may prove valuable in understanding the receptors mediating opioid pharmacology.

Original languageEnglish
Pages (from-to)805-810
Number of pages6
JournalNeuron
Volume12
Issue number4
DOIs
StatePublished - May 3 1994
Externally publishedYes

Fingerprint

Oligodeoxyribonucleotides
Opioid Receptors
Analgesia
Opioid Analgesics
Pharmacology
Analgesics
Spinal Cord

ASJC Scopus subject areas

  • Neuroscience(all)

Cite this

Selective loss of δ opioid analgesia and binding by antisense oligodeoxynucleotides to a δ opioid receptor. / Standifer, Kelly M.; Chien, Chih Cheng; Wahlestedt, Claes R; Brown, George P.; Pasternak, Gavril W.

In: Neuron, Vol. 12, No. 4, 03.05.1994, p. 805-810.

Research output: Contribution to journalArticle

Standifer, Kelly M. ; Chien, Chih Cheng ; Wahlestedt, Claes R ; Brown, George P. ; Pasternak, Gavril W. / Selective loss of δ opioid analgesia and binding by antisense oligodeoxynucleotides to a δ opioid receptor. In: Neuron. 1994 ; Vol. 12, No. 4. pp. 805-810.
@article{dfa3a30d62824f098305b25ff78f2b5c,
title = "Selective loss of δ opioid analgesia and binding by antisense oligodeoxynucleotides to a δ opioid receptor",
abstract = "Antisense oligodeoxynucleotides (18-20 bases) to a cloned δ opioid receptor (DOR-1) lower δ binding in NG108-15 cells by 40{\%}-50{\%}. Changing 4 bases to generate a mismatch antisense oligodeoxynucleotide or mixing the corresponding sense and antisense oligodeoxynucleotides prior to treatment of the cells eliminates the inhibition of binding, confirming the specificity of the response. In vivo, an antisense oligodeoxynucleotide to DOR-1 given intrathecally lowers δ, but not μ or κ1 spinal analgesia. The mismatch antisense oligodeoxynucleotide is inactive. δ analgesic sensitivity gradually returns by 5 days after the last antisense treatment, indicating the lack of irreversible damage or toxicity. These studies demonstrate that DOR-1 mediates δ analgesia at the level of the spinal cord and confirm at the molecular level traditional pharmacological studies implying distinct receptor mechanisms for δ, μ, and κ1 analgesia. The use of antisense approaches may prove valuable in understanding the receptors mediating opioid pharmacology.",
author = "Standifer, {Kelly M.} and Chien, {Chih Cheng} and Wahlestedt, {Claes R} and Brown, {George P.} and Pasternak, {Gavril W.}",
year = "1994",
month = "5",
day = "3",
doi = "10.1016/0896-6273(94)90333-6",
language = "English",
volume = "12",
pages = "805--810",
journal = "Neuron",
issn = "0896-6273",
publisher = "Cell Press",
number = "4",

}

TY - JOUR

T1 - Selective loss of δ opioid analgesia and binding by antisense oligodeoxynucleotides to a δ opioid receptor

AU - Standifer, Kelly M.

AU - Chien, Chih Cheng

AU - Wahlestedt, Claes R

AU - Brown, George P.

AU - Pasternak, Gavril W.

PY - 1994/5/3

Y1 - 1994/5/3

N2 - Antisense oligodeoxynucleotides (18-20 bases) to a cloned δ opioid receptor (DOR-1) lower δ binding in NG108-15 cells by 40%-50%. Changing 4 bases to generate a mismatch antisense oligodeoxynucleotide or mixing the corresponding sense and antisense oligodeoxynucleotides prior to treatment of the cells eliminates the inhibition of binding, confirming the specificity of the response. In vivo, an antisense oligodeoxynucleotide to DOR-1 given intrathecally lowers δ, but not μ or κ1 spinal analgesia. The mismatch antisense oligodeoxynucleotide is inactive. δ analgesic sensitivity gradually returns by 5 days after the last antisense treatment, indicating the lack of irreversible damage or toxicity. These studies demonstrate that DOR-1 mediates δ analgesia at the level of the spinal cord and confirm at the molecular level traditional pharmacological studies implying distinct receptor mechanisms for δ, μ, and κ1 analgesia. The use of antisense approaches may prove valuable in understanding the receptors mediating opioid pharmacology.

AB - Antisense oligodeoxynucleotides (18-20 bases) to a cloned δ opioid receptor (DOR-1) lower δ binding in NG108-15 cells by 40%-50%. Changing 4 bases to generate a mismatch antisense oligodeoxynucleotide or mixing the corresponding sense and antisense oligodeoxynucleotides prior to treatment of the cells eliminates the inhibition of binding, confirming the specificity of the response. In vivo, an antisense oligodeoxynucleotide to DOR-1 given intrathecally lowers δ, but not μ or κ1 spinal analgesia. The mismatch antisense oligodeoxynucleotide is inactive. δ analgesic sensitivity gradually returns by 5 days after the last antisense treatment, indicating the lack of irreversible damage or toxicity. These studies demonstrate that DOR-1 mediates δ analgesia at the level of the spinal cord and confirm at the molecular level traditional pharmacological studies implying distinct receptor mechanisms for δ, μ, and κ1 analgesia. The use of antisense approaches may prove valuable in understanding the receptors mediating opioid pharmacology.

UR - http://www.scopus.com/inward/record.url?scp=0028327150&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028327150&partnerID=8YFLogxK

U2 - 10.1016/0896-6273(94)90333-6

DO - 10.1016/0896-6273(94)90333-6

M3 - Article

VL - 12

SP - 805

EP - 810

JO - Neuron

JF - Neuron

SN - 0896-6273

IS - 4

ER -